Introduction: In esthetic treatments with
INTRODUCTION
.
PCL is a totally bioresorbable, nontoxic medical polymer and is attractive for use in medical devices because of its controlled and safe bioresorption process [7] [8] [9] [10] [11] . With 3 H-labeled PCL and C 14 -labeled PCL implantation studies, it has been proved that PCL was completely excreted from the body [7, 8] .
After treatment the CMC gel carrier is gradually resorbed by macrophages over a period of several weeks, during which the PCL microspheres will trigger a natural response of the human skin and stimulate a natural woundhealing process through neocollagenesis. The new collagen replaces the volume of the resorbed carrier. The microspheres are not phagocytosed because of their size and surface characteristics. The PCL microspheres are totally smooth and spherical shaped, which has been shown to be optimal for dermal fillers [12, 13] . The PCL dermal filler is indicated for deep dermal and subdermal implantation.
In 2007 Busso and Applebaum [14] 
MATERIALS AND METHODS

Study Purpose and Design
In this study the characterization of the Tinius Olsen, Ltd., Salfords, Surrey, UK). Extrusion force was evaluated through a 27G
inch needle with an extension rate of 1 mL/min. Media pH was measured using a pH meter with a probe (pH340I, and Sentix 41 probe, respectively; WTW, Weilheim, Germany). Lidocaine and PCL dermal filler were mixed by alternately depressing the plungers on the mixing and media syringes. Each mixing stroke was composed of one complete compression of the dermal filler syringe push rod, followed by one complete compression of the mixing syringe push rod. Push rods were compressed firmly and quickly, at approximately two compressions per second.
Following mixing, the mixing syringe and Luer lock connector were removed and discarded, and the lidocaine/dermal filler mixture was recapped with the original media Differences in average extrusion force for PCL dermal filler mixed with lidocaine with and without epinephrine was not statistically significant for all volumes, suggesting that epinephrine had no effect on the extrusion force. The pH was between 7.1 and 7.2 for all tested samples. This study does not address a potential interaction of lidocaine or epinephrine with the components of the PCL dermal filler and its potential influence on anesthetic efficacy. It is expected that, because of its hydrophilicity, lidocaine will be situated in the aqueous (hydrophilic) CMC gel carrier. Predicted on the hydrophobicity of the nonporous PCL microspheres [22] no affinity is expected between lidocaine and PCL microspheres, and there will be no driving force of the lidocaine to migrate into the PCL microspheres. This is supported by a study describing the release profile of lidocaine from PCL threads [23] . PCL pellets were compounded with lidocaine and then extruded to obtain highly loaded threads. The lidocaine release profile showed a rapid release in the first hours and completed in a few days, indicating that there is no affinity or reaction between the PCL matrix and lidocaine.
It is not expected that lidocaine will bind or react with the CMC carrier, but is free to move and yield the desired anesthetic effect. CMC is a known time-release agent for lidocaine [24] , and there are several commercial medical products available based on CMC gel and lidocaine as an anesthetic agent. 
CONCLUSION
The advantages of mixing lidocaine with PCL dermal filler before treatment are lower viscosity and elasticity, lower extrusion force, providing a greater ease of molding, increased patient comfort, reduced need for nerve blocks and infiltration anesthesia, which may be attractive for both physicians and patients.
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